lobbying_activities: 3005841

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3005841	b3860da1-d311-4999-a41f-76a8976b954a	Q2	PORT SIDE STRATEGIES, LLC	401105394	NEW VENTURE FUND	2023	second_quarter	PHA	Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed. S. 1264 - SMART Prices Act - in support. S. 1323 - End Price Gouging for Medications Act - in support. S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed. S. 1339 - Pharmacy Benefit Manager Reform Act - in support. S. 1214 - RARE Act - in support. S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 - in support. S.1067 - Ensuring Timely Access to Generics Act of 2023 - in support.	HOUSE OF REPRESENTATIVES,SENATE			0	0	2023-07-16T15:00:08-04:00